Loading data for AGIO — first visit, this takes a few seconds.

Alert

Agios Pharmaceuticals Inc... (AGIO)

NasdaqGS: AGIO · Real-Time Price · USD

33.63

-1.49 (-4.24%)

At close: Aug 20, 2026, 8:00 PM

The price, the headline numbers and the latest news, in one place.

-4.24% (1D)

No data available

Bid	24.95
Market Cap	2.01B
Revenue (ttm)	98.34M
Net Income (ttm)	-411.29M
	0.59
	-6.71
	n/a
	-8.52
P/B (ttm)	1.95
P/S (ttm)	20.42
Earnings Date	Oct 29, 2026

Ask	43.34
Volume	697,492
Avg. Volume (20D)	1,172,008
Open	34.64
Previous Close	35.12
Day's Range	33.61 - 35.09
52-Week Range	22.24 - 46.00
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About AGIO

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 24, 2013

Employees 539

Stock Exchange NasdaqGS

Ticker Symbol AGIO

Website https://www.agios.com

Full Company Profile

Financial Performance

In 2025, Agios Pharmaceuticals's revenue was 54.03M, an increase of 48.03% compared to the previous year's 36.5M. Earnings were -412.78M, a decrease of -161.27%.

Financial Statements

Earnings Surprise

Agios Pharmaceuticals has released their quarterly earnings on Jul 30, 2026:

Revenue of $44.74M misses estimates by $0, with 259.25% YoY growth.

EPS of -1.69 misses estimates by -0.03, with 12.44% YoY growth.

Next Earnings Release

Agios Pharmaceuticals Inc. is scheduled to release its earnings on Oct 29, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

2 weeks ago · Zacks

AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year

Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.

3 weeks ago · GuruFocus.com

Agios Pharmaceuticals Inc (AGIO) (Q2 2026) Earnings Call Highlights: Strong Mitapivat Revenue ...

Agios reports $44.7 million in Q2 mitapivat revenue and FDA priority review for sickle cell disease, while advancing pipeline diversification with cevidoplenib.

3 weeks ago · MarketBeat

Agios Pharmaceuticals Q2 Earnings Call Highlights

Agios Pharmaceuticals (NASDAQ:AGIO) reported second-quarter 2026 mitapivat net revenue of $44.7 million, including $40.9 million in the United States and $3.8 million outside the U.S., as the company ...

3 weeks ago · Zacks

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +9.14% and +97.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago · Simply Wall St.

Tebapivat Sickle Cell Setback and Mitapivat Priority Review Could Be A Game Changer For Agios (AGIO)

In July 2026, Agios Pharmaceuticals reported topline Phase 2 results for tebapivat in sickle cell disease, showing hemoglobin and hemolysis improvements but insufficient differentiation versus placebo...

Page 1 of 2

Agios Pharmaceuticals Inc... (AGIO)